PHP
MRTX

Parkman Healthcare Partners’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Parkman Healthcare Partners’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15,236
Closed -$1.25M – 90
2022
Q1 		$1.25M Buy
15,236
+2,322
+18% +$237K 0.37% 61
2021
Q4 		$1.89M Buy
+12,914
New +$2M 0.42% 62

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Parkman Healthcare Partners's MRTX Position: Q2 2022 in Review

Parkman Healthcare Partners sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2022, closing a stake of 15,236 shares — an estimated $1.25M sold.

Parkman Healthcare Partners first reported a position in MRTX in Q4 2021 and held it in 2 quarters. The position peaked at $1.89M in Q4 2021. 230 funds tracked by Wall St. Rank hold MRTX as of Q2 2022.

  • Parkman Healthcare Partners reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Parkman Healthcare Partners sold 15,236 Mirati Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $1.25M.
  • Parkman Healthcare Partners first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Parkman Healthcare Partners's Mirati Therapeutics, Inc. Common Stock position peaked at $1.89M in Q4 2021.
  • 230 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Parkman Healthcare Partners's 13F filing for Q2 2022, filed 12 Aug 2022.